Maven Securities LTD purchased a new stake in Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 29,930 shares of the company's stock, valued at approximately $613,000. Maven Securities LTD owned 0.08% of Rapport Therapeutics as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of RAPP. Eventide Asset Management LLC grew its stake in Rapport Therapeutics by 120.8% in the 3rd quarter. Eventide Asset Management LLC now owns 110,401 shares of the company's stock valued at $2,261,000 after buying an additional 60,401 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Rapport Therapeutics in the third quarter valued at about $117,000. BNP Paribas Financial Markets bought a new position in shares of Rapport Therapeutics in the third quarter worth about $34,000. FMR LLC increased its stake in shares of Rapport Therapeutics by 10.1% in the third quarter. FMR LLC now owns 5,486,468 shares of the company's stock worth $112,363,000 after purchasing an additional 503,117 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Rapport Therapeutics by 2.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company's stock worth $1,584,000 after purchasing an additional 1,828 shares during the last quarter.
Rapport Therapeutics Stock Down 6.0 %
RAPP traded down $1.29 during midday trading on Thursday, reaching $20.27. The company's stock had a trading volume of 116,996 shares, compared to its average volume of 153,899. The firm has a fifty day simple moving average of $23.19. Rapport Therapeutics has a twelve month low of $16.55 and a twelve month high of $29.74.
About Rapport Therapeutics
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
